DK2861582T3 - A process for preparing hydroxylated compounds cyclopentylpyrimidin - Google Patents

A process for preparing hydroxylated compounds cyclopentylpyrimidin Download PDF

Info

Publication number
DK2861582T3
DK2861582T3 DK13725042.9T DK13725042T DK2861582T3 DK 2861582 T3 DK2861582 T3 DK 2861582T3 DK 13725042 T DK13725042 T DK 13725042T DK 2861582 T3 DK2861582 T3 DK 2861582T3
Authority
DK
Denmark
Prior art keywords
substituted
unsubstituted
compound
alkyl
salt
Prior art date
Application number
DK13725042.9T
Other languages
Danish (da)
English (en)
Inventor
David Askin
Chong Han
Jonathan W Lane
Travis Remarchuk
Sagar Shakya
C Gregory Sowell
Keith L Spencer
Peter J Stengel
Original Assignee
Array Biopharma Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc
Application granted granted Critical
Publication of DK2861582T3 publication Critical patent/DK2861582T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
DK13725042.9T 2012-05-17 2013-05-17 A process for preparing hydroxylated compounds cyclopentylpyrimidin DK2861582T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648473P 2012-05-17 2012-05-17
US201361785122P 2013-03-14 2013-03-14
PCT/US2013/041666 WO2013173768A1 (en) 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds

Publications (1)

Publication Number Publication Date
DK2861582T3 true DK2861582T3 (en) 2016-08-22

Family

ID=48485537

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13725042.9T DK2861582T3 (en) 2012-05-17 2013-05-17 A process for preparing hydroxylated compounds cyclopentylpyrimidin

Country Status (20)

Country Link
US (4) US9416110B2 (enExample)
EP (1) EP2861582B1 (enExample)
JP (1) JP6284928B2 (enExample)
KR (1) KR102067850B1 (enExample)
CN (1) CN104470913B (enExample)
AU (1) AU2013262505B2 (enExample)
BR (1) BR112014028589B1 (enExample)
CA (1) CA2873654C (enExample)
DK (1) DK2861582T3 (enExample)
ES (1) ES2582557T3 (enExample)
IL (1) IL235715A (enExample)
MX (1) MX353384B (enExample)
MY (1) MY169028A (enExample)
NZ (1) NZ702935A (enExample)
PL (1) PL2861582T3 (enExample)
RU (1) RU2643811C2 (enExample)
SG (1) SG11201407616TA (enExample)
SI (1) SI2861582T1 (enExample)
WO (1) WO2013173768A1 (enExample)
ZA (1) ZA201409261B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173736A1 (en) 2012-05-17 2013-11-21 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
PE20150725A1 (es) 2012-05-17 2015-05-17 Genentech Inc Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y metodos de este
NZ702950A (en) 2012-05-17 2016-09-30 Genentech Inc Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
CA2873654C (en) 2012-05-17 2021-06-22 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
ES2957314T3 (es) 2013-11-15 2024-01-17 Hoffmann La Roche Procesos para la preparación de compuestos de pirimidinilciclopentano
SG11201702324QA (en) * 2014-09-26 2017-04-27 Hoffmann La Roche PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS
CN109789141B (zh) 2016-08-10 2022-08-26 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物
MX2022015322A (es) 2020-06-16 2023-01-11 Hoffmann La Roche Proceso para elaborar compuestos de ciclopentilpirimidina hidroxilada.
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1134212C (zh) 1993-12-12 2004-01-14 阿格罗吉恩有限公司 保护植物免受真菌侵染的新方法
AU724216B2 (en) 1997-04-07 2000-09-14 Merck & Co., Inc. A method of treating cancer
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
US6376496B1 (en) 1999-03-03 2002-04-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CN1281604C (zh) * 1999-06-03 2006-10-25 帝国脏器制药株式会社 取代吡唑化合物
WO2001022963A1 (en) 1999-09-27 2001-04-05 Merck & Co., Inc. Method of preventing osteoporosis
WO2004108673A2 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
CA2758484A1 (en) 2009-04-15 2010-10-21 David A. Degoey Anti-viral compounds
JP5581390B2 (ja) * 2009-10-23 2014-08-27 イーライ リリー アンド カンパニー Akt阻害剤
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
PE20150725A1 (es) 2012-05-17 2015-05-17 Genentech Inc Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y metodos de este
CA2873658C (en) 2012-05-17 2021-01-26 Genentech, Inc. Process for making amino acid compounds
CA2873654C (en) 2012-05-17 2021-06-22 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
WO2013173736A1 (en) 2012-05-17 2013-11-21 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
NZ702950A (en) 2012-05-17 2016-09-30 Genentech Inc Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
US20140121193A1 (en) 2012-11-01 2014-05-01 Robert S. Katz Methods for treating fibromyalgia
EP2956441A4 (en) 2013-02-18 2016-11-02 Scripps Research Inst MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL
US10131637B2 (en) 2013-03-15 2018-11-20 Shifa Biomedical Corporation Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases

Also Published As

Publication number Publication date
KR102067850B1 (ko) 2020-01-17
US9676730B2 (en) 2017-06-13
ES2582557T3 (es) 2016-09-13
US20180258054A1 (en) 2018-09-13
EP2861582B1 (en) 2016-05-25
US20170247337A1 (en) 2017-08-31
US20160318877A1 (en) 2016-11-03
EP2861582A1 (en) 2015-04-22
US9790190B2 (en) 2017-10-17
ZA201409261B (en) 2017-05-31
MX353384B (es) 2018-01-10
JP6284928B2 (ja) 2018-02-28
BR112014028589B1 (pt) 2022-08-23
KR20150020214A (ko) 2015-02-25
BR112014028589A2 (pt) 2017-07-25
SI2861582T1 (sl) 2016-09-30
NZ702935A (en) 2017-02-24
US20150152067A1 (en) 2015-06-04
SG11201407616TA (en) 2015-03-30
PL2861582T3 (pl) 2016-11-30
WO2013173768A1 (en) 2013-11-21
MX2014013862A (es) 2015-05-07
CA2873654C (en) 2021-06-22
RU2643811C2 (ru) 2018-02-06
HK1208451A1 (en) 2016-03-04
AU2013262505A1 (en) 2015-01-22
AU2013262505B2 (en) 2017-09-21
IL235715A (en) 2017-02-28
IL235715A0 (en) 2015-02-01
US9416110B2 (en) 2016-08-16
CN104470913B (zh) 2018-07-20
CN104470913A (zh) 2015-03-25
JP2015517532A (ja) 2015-06-22
MY169028A (en) 2019-02-04
RU2014151050A (ru) 2016-07-10
CA2873654A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
DK2861582T3 (en) A process for preparing hydroxylated compounds cyclopentylpyrimidin
AU2019253849B2 (en) Processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
EP2850054B1 (en) Process for making amino acid compounds
HK40024946B (en) Process for preparing an intermediate in the synthesis of (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
HK40024946A (en) Process for preparing an intermediate in the synthesis of (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
HK1208451B (zh) 用於製造羥基化的環戊基嘧啶化合物的方法